Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 4/20 | 0.50 |
| ▸ | CTSS | P25774 | 2/20 | 0.50 |
| ▸ | CTSK | P43235 | 5/20 | 0.49 |
| ▸ | CASP1 | P29466 | 3/20 | 0.48 |
| ▸ | CA12 | O43570 | 2/20 | 0.47 |
| ▸ | CA1 | P00915 | 2/20 | 0.47 |
| ▸ | CA2 | P00918 | 2/20 | 0.47 |
| ▸ | CA9 | Q16790 | 2/20 | 0.47 |
| ▸ | SIRT2 | Q8IXJ6 | 3/20 | 0.46 |
| ▸ | SIRT1 | Q96EB6 | 2/20 | 0.46 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.46 |
| ▸ | CTSB | P07858 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4035779 | 1.00 | CTSL (0.50) | CTSLCTSSCTSKCASP1CA12 | |
| SCHEMBL4035564 | 0.88 | CTSL (0.52) | CTSLCTSSCTSKCASP1CA12 | |
| SCHEMBL4035562 | 0.88 | CTSL (0.52) | CTSLCTSSCTSKCASP1CA12 | |
| SCHEMBL1290957 | 0.86 | CTSL (0.52) | CTSLCTSSCTSKCASP1SIRT2 | |
| SCHEMBL1290959 | 0.86 | CTSL (0.52) | CTSLCTSSCTSKCASP1SIRT2 | |
| SCHEMBL4031080 | 0.86 | SIRT2 (0.48) | CTSLCTSSCTSKCASP1SIRT2 | |
| SCHEMBL6139194 | 0.83 | CTSL (0.61) | CTSLCTSSCTSKCASP1CTSB | |
| SCHEMBL27616333 | 0.83 | CTSL (0.61) | CTSLCTSSCTSKCASP1CTSB | |
| SCHEMBL4031076 | 0.83 | CTSL (0.47) | CTSLCTSSCTSKCASP1SIRT2 | |
| SCHEMBL29399827 | 0.82 | CTSL (0.54) | CTSLCTSSCTSKSIRT2SIRT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090312260-A1 | DRUG THERAPY FOR CELIAC SPRUE | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2009-12-17 | — | — | US | disclosed |
| US-7605150-B2 | Drug therapy for Celiac Sprue | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2009-10-20 | — | — | US | disclosed |
| EP-1507549-A4 | DRUG THERAPY FOR CELIAC SPRUE | UNIV LELAND STANFORD JUNIOR (US) | 2009-07-01 | — | — | EP | disclosed |
| US-20060035838-A1 | Drug therapy for celiac sprue | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2006-02-16 | — | — | US | disclosed |
| EP-1507549-A2 | DRUG THERAPY FOR CELIAC SPRUE | The Board of Trustees of The Leland Stanford Junior University (US) | 2005-02-23 | — | — | EP | disclosed |
| WO-2003096979-A2 | DRUG THERAPY FOR CELIAC SPRUE | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2003-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060035838-A1 | Drug therapy for celiac sprue | SI, TMPRSS15, DNPEP | CTSL 172/4885CTSS 264/4885CTSK 456/4885 |
| US-20090312260-A1 | DRUG THERAPY FOR CELIAC SPRUE | SI, DNPEP, SPINT2 | CTSL 188/4885CTSS 163/4885CTSK 184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.